Clinical trials: COVID-19
COVID-19, Long COVID
BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients
This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lung function in patients that were hospitalized for severe…
- Conditions
- COVID-19, Long COVID, Pulmonary Fibrosis, Post-acute Respiratory Complications of COVID-19
- Trial name
- NCT04482595
- Testing
- BIO 300 Oral Suspension
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Humanetics Corporation
COVID-19, Influenza A
Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use
The goal of this study is to evaluate the performance of the COVID/Flu Detect™ Rapid Self-Test when used in a home-like setting by lay users.
- Conditions
- COVID-19, Influenza A, Influenza B
- Trial name
- NCT06734741
- Testing
- COVID/Flu Detect™ Rapid Self-Test
- Where
- 10 sites in United States
- Volunteers
- 899 people
- Sponsor
- InBios International, Inc.
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants
The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical COVID-19, as compared to placebo, in adult participants.
- Trial name
- ENSEMBLE (NCT04505722)
- Testing
- Ad26.COV2.S
- Where
- 225 sites in United States, Argentina and 6 more
- Volunteers
- 44,325 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
COVID-19
Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
- Trial name
- NCT04603651
- Testing
- Bamlanivimab
- Sponsor
- Eli Lilly and Company
SARS-CoV-2 Infection
A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19
Clinical trial to compare sublingual low does thimerosal in adults that have symptoms of SARS-CoV-2 Infection against placebo to show a difference in physical characteristics and viral levels.
- Trial name
- BTL-TML-COVID (NCT04522830)
- Testing
- BTL-TML-COVID
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Beech Tree Labs, Inc.
COVID-19
Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19
The purpose of this study is to evaluate the efficacy and safety of XAV-19 drug in patients with moderate-to-severe COVID-19.
- Trial name
- NCT04928430
- Testing
- XAV-19
- Where
- 18 sites in Bulgaria, Greece and 3 more
- Volunteers
- 290 people
- Sponsor
- Xenothera SAS
Post Acute COVID-19 Syndrome
Digital Health Intervention Based on Artificial Intelligence to Support the Personalized Recovery of Long COVID Patients Affected by Fatigue (AIDA)
The AIDA feasibility study builds upon mental health and technology acceptance theoretical frameworks. It examines the feasibility of a mobile-based digital program to support patients with long covid affected by fatigue.
- Trial name
- AIDA (NCT05483829)
- Testing
- Adhera® Fatigue for Long COVID program
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Adhera Health, Inc.
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
VBI-2901a is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05548439
- Testing
- VBI-2901a
- Where
- 7 sites in Canada
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
COVID-19
Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19
This is a double-blind, multicentre, multinational study to evaluate the safety and collect preliminary efficacy data of Codivir drug product in 130 hospitalized adults with moderate COVID-19 symptoms.
- Trial name
- NCT05218356
- Testing
- Covidir injections, Quantitative PCR SARS-CoV-2, IgM and IgG dosage
- Where
- 5 sites in Brazil
- Volunteers
- 130 people
- Sponsor
- Code Pharma
COVID-19 Respiratory Infection, Acute Respiratory Disease
Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19
It is known that the pretreatment with exogenous interferon blocks SARS-CoV-2 infection, but intervention is much more effective if administered prior to infection.
- Trial name
- NCT05054114
- Testing
- Interferon gamma human recombinant (IFN-G)
- Where
- Russia
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- SPP Pharmaclon Ltd.
Depression, Post-COVID-19 Syndrome
Evaluation of DEPREXIL in Patients With Clinical Depression Through Psychological and Neuroendocrine Assessment
Clinical depression is a mood disorder that affects people of all ages with symptoms such as sadness, anger or frustration, appetite changes, difficulty concentrating and suicidal thoughts.
- Conditions
- Depression, Post-COVID-19 Syndrome, Depression Mild, Depression Moderate
- Trial name
- NCT06496087
- Testing
- DEPREXIL
- Where
- Colombia
- Volunteers
- 100 people
- Sponsor
- Catalysis SL
COVID-19
Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR)
The acute pneumonia pandemic caused by a new strain of corona virus 2019 named as COVID-19 by the World Health Organization (WHO) is a pandemic caused by SARS-CoV-2 virus.
- Trial name
- KOVIR (NCT05042141)
- Testing
- KOVIR oral capsule
- Where
- Vietnam
- Volunteers
- 66 people
- Sponsor
- Sao Thai Duong Joint Stock Company
COVID-19
A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above
This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years…
- Trial name
- COVID-19 (NCT04510207)
- Testing
- Inactivated SARS-CoV-2 Vaccine (Vero cell)
- Where
- 6 sites in Bahrain, Egypt and 2 more
- Volunteers
- 44,101 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Covid19, Pneumonia, Viral
Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19
Evaluate the safety pharmacokinetics and pharmacodynamics (PK/PD)of a single dose of Kamada anti-severe acute respiratory syndrome (SARS)- CoV-2 in patients hospitalized with COVID-19 caused pneumonia
- Trial name
- NCT04550325
- Testing
- Kamada Anti-SARS-CoV-2
- Where
- 4 sites in Israel
- Volunteers
- 12 people
- Sponsor
- Kamada, Ltd.
Covid19 Vaccine
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults
The purpose of this study is to assess the immunogenicity and safety of MVC-COV1901 vaccine compared to AZD1222 in heathy adults.
- Trial name
- NCT05011526
- Testing
- MVC-COV1901, AZD1222
- Where
- 2 sites in Paraguay
- Volunteers
- 1,030 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
COVID-19 Pneumonia
Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Renal Function
This si a single-center, non-randomized, open, parallel, single-dose trial was designed to evaluate the safety and pharmacokinetic characteristics of GST-HG171 tablets in subjects with impaired renal function.
- Trial name
- NCT06106126
- Testing
- GST-HG171 Tablets
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)
This is a Phase IIb, randomized, controlled, observer-blinded, clinical trial to evaluate safety and immunogenicity of COVID-19 Vaccine HIPRA in adult healthy volunteers in Vietnam
- Trial name
- NCT05142514
- Testing
- COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech)
- Where
- Vietnam
- Volunteers
- 629 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
COVID-19 Respiratory Infection
ALACOVID Study for Vaccinated Subjects
In this study, it is hypothesized that administration of 5-ALA-Phosphate + SFC in subjects vaccinated against Covid-19 could contribute in enhancing the targeted function of the immune system, which might lead to re-activation…
- Trial name
- COVID-19 (NCT05234346)
- Testing
- 150 mg 5-ALAPhosphate + SFC
- Where
- 4 sites in India
- Volunteers
- 200 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Coronavirus, COVID
Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar
Coronavirus Disease 2019 (COVID-19) is a disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus.
- Conditions
- Coronavirus, COVID, Pneumonia
- Trial name
- DOLCI (NCT04425382)
- Testing
- Darunavir/Cobicistat, Lopinavir/Ritonavir
- Where
- Qatar
- Volunteers
- 400 people
- Sponsor
- Hamad Medical Corporation
COVID-19
Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine
The main purposes of this research study are to measure the safety (whether it causes any side effects), tolerability (if it does cause any side effects, how well your body is able to handle them), and reactions, both local at…
- Trial name
- LIBERTY (NCT07655180)
- Testing
- COVID-19 mRNA vaccine, VYD2311
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Invivyd, Inc.